Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ficlatuzumab × Other hematologic neoplasm × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other hematologic neoplasm 1 Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 412 Cytarabine 335 fludarabine phosphate 229 Rituximab 205 Methotrexate 198 fludarabine 193 Azacitidine 171 venetoclax 170 Busulfan 168 Filgrastim 145 Whole-Body Irradiation 142 Mycophenolic Acid 142 Peripheral Blood Stem Cell Transplantation 140 Tacrolimus 136 Etoposide 130 Vincristine 111 Melphalan 108 Dexamethasone 108 Cyclosporine 101 Granulocyte Colony-Stimulating Factor 100 Imatinib Mesylate 94 Antilymphocyte Serum 91 Daunorubicin 89 Radiotherapy 84 Decitabine 83 Dasatinib 76 Lenalidomide 74 Doxorubicin 69 Prednisone 68 Idarubicin 68

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡